All Articles

Next-generation sequencing for targetable mutations in lung cancer is as accurate as single-gene testing with minimal increase in testing cost.

Released study results indicate that an interval of ≤50 days from diagnosis to treatment significantly improves outcomes in patients with early-stage lung cancer.

A recent review article examined the limited benefit associated with immune checkpoint inhibitor use in patients with non–small-cell lung cancer with poor performance status.

Smoking cessation ≥3 weeks prior to lung cancer surgery significantly decreases postoperative complications.

This review outlines treatment sequencing considerations for patients with recurrent ovarian cancer.

Results of the phase 2b VITAL trial suggest that immunotherapy with the autologous tumor cell vaccine gemogenovatucel-T as frontline maintenance in stage III/IV ovarian cancer is well-tolerated and shows clinical benefit in both BRCA-wild type and homologous recombination–proficient subgroups.

Patient-reported outcomes of tolerability with adavosertib indicated greater incidence of fatigue, diarrhea, mucositis, and difficulty swallowing in patients receiving adavosertib and gemcitabine; however, no significant differences were noted in the symptomatic adverse-event profile for gastrointestinal events and anxiety.

Results of the phase 1b FORWARD II trial show that the MIRV/bevacizumab combination demonstrates promising antitumor activity with durable responses and favorable tolerability in high FRα recurrent ovarian cancer.